EQUITY RESEARCH MEMO

SiteCentric

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)72/100

SiteCentric provides a comprehensive clinical trial management software (CTMS) platform tailored specifically for clinical research sites. Founded in 2016 and headquartered in Boston, the company's all-in-one solution integrates business development, electronic investigator site files (eISF), CTMS, finance, and reporting. By leveraging over 25 years of collective site experience, SiteCentric addresses the operational inefficiencies that plague clinical research sites, enabling streamlined workflows, improved data accuracy, and reduced administrative burdens. The platform's intuitive design and unified interface help sites manage complex trials more efficiently, ultimately lowering costs and accelerating study timelines. As the clinical trial landscape grows increasingly decentralized and data-intensive, SiteCentric is well-positioned to capture market share by offering a purpose-built solution that enhances site productivity and competitiveness. SiteCentric operates in the rapidly expanding digital health and clinical trials segment, where the demand for site-friendly technology is surging. With a strong value proposition centered on 'built by sites, for sites,' the company differentiates itself from larger, more generic CTMS providers. Its focus on the underserved site market, coupled with a modular yet integrated platform, positions it for sustained growth. While the company remains private and its financials are undisclosed, its niche focus and experienced team suggest a promising trajectory. Emerging trends such as decentralized trials and increased site digitization further bolster its potential. SiteCentric is poised to become a key enabler for research sites seeking to optimize operations and participate in more trials.

Upcoming Catalysts (preview)

  • Q4 2026Partnership with a Top-10 CRO for Preferred Supplier Agreement60% success
  • Q2 2026Release of AI-Powered Patient Recruitment Module75% success
  • Q3 2026Series B Funding Round of $15-20M50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)